Effects of long-term oxygen therapy on acute exacerbation and hospital burden: the national DISCOVERY studyShow others and affiliations
2025 (English)In: Thorax, ISSN 0040-6376, E-ISSN 1468-3296, article id thorax-2023-221063Article in journal (Refereed) Epub ahead of print
Abstract [en]
BACKGROUND: Long-term oxygen therapy (LTOT) improves survival in patients with chronic severe resting hypoxaemia, but effects on hospitalisation are unknown. This study evaluated the potential impact of starting LTOT on acute exacerbation and hospital burden in patients with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD) and pulmonary hypertension (PH).
METHODS: Longitudinal analysis of consecutive patients in the population-based Swedish DISCOVERY cohort who started LTOT between 2000 and 2018 with a follow-up duration≥3 months. Total and hospitalised acute exacerbations of the underlying disease, all-cause hospitalisations, and all-cause outpatient visits were annualised and compared between the year before and after LTOT initiation for each disease cohort, and by hypercapnic status in patients with COPD.
RESULTS: Patients with COPD (n=10 134) had significant reduction in annualised rates of total and hospitalised acute exacerbations, as well as all-cause hospitalisations, following LTOT initiation, with increment in those with ILD (n=2507) and PH (n=850). All-cause outpatient visits increased across all cohorts following LTOT initiation. Similar findings were observed in patients with hypercapnic and non-hypercapnic COPD. Sensitivity analyses of patients with 12 months of follow-up showed reduced acute exacerbations and all-cause hospitalisations in the ILD and PH cohorts.
CONCLUSION: LTOT is associated with reduced rates of both total and hospitalised acute exacerbations and all-cause hospitalisations in patients with COPD, as well as patients with ILD and PH with 12 months of follow-up. There is increased all-cause outpatient visits in all disease groups following LTOT initiation.
Place, publisher, year, edition, pages
BMJ Publishing Group Ltd, 2025. article id thorax-2023-221063
Keywords [en]
COPD Exacerbations, Hypoxemia, Idiopathic pulmonary fibrosis, Interstitial Fibrosis, Long Term Oxygen Therapy (LTOT), Primary Pulmonary Hypertension
National Category
Respiratory Medicine and Allergy
Identifiers
URN: urn:nbn:se:oru:diva-120136DOI: 10.1136/thorax-2023-221063ISI: 001449183900001PubMedID: 40113248Scopus ID: 2-s2.0-105000655595OAI: oai:DiVA.org:oru-120136DiVA, id: diva2:1946419
Funder
Swedish Heart Lung Foundation, 20200295Swedish Research Council, 2019-02081
Note
YHK receives fellowship support from the National Health and Medical Research Council Investigator Grant (ID: 2008255). ZA was supported by the Swedish Heart-Lung Foundation (ID: 20200295). ME was supported by an unrestricted grant from the Swedish Research Council (ID: 2019-02081).
2025-03-212025-03-212025-04-03Bibliographically approved